BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38175707)

  • 21. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
    Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
    Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas.
    Staedtke V; Topilko P; Le LQ; Grimes K; Largaespada DA; Cagan RL; Steensma MR; Stemmer-Rachamimov A; Blakeley JO; Rhodes SD; Ly I; Romo CG; Lee SY; Serra E
    J Invest Dermatol; 2023 Aug; 143(8):1378-1387. PubMed ID: 37330719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations.
    Serra E; Rosenbaum T; Winner U; Aledo R; Ars E; Estivill X; Lenard HG; Lázaro C
    Hum Mol Genet; 2000 Dec; 9(20):3055-64. PubMed ID: 11115850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEK inhibitors in RASopathies.
    Bergqvist C; Wolkenstein P
    Curr Opin Oncol; 2021 Mar; 33(2):110-119. PubMed ID: 33395032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
    Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
    Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
    Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
    Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
    Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
    Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
    Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
    Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
    Rhodes SD; McCormick F; Cagan RL; Bakker A; Staedtke V; Ly I; Steensma MR; Lee SY; Romo CG; Blakeley JO; Sarin KY
    J Invest Dermatol; 2023 Aug; 143(8):1358-1368. PubMed ID: 37245145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
    Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
    Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.
    Fischer-Huchzermeyer S; Dombrowski A; Wilke G; Stahn V; Streubel A; Mautner VF; Harder A
    PLoS One; 2017; 12(11):e0187700. PubMed ID: 29131833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ogerin mediated inhibition of TGF-β(1) induced myofibroblast differentiation is potentiated by acidic pH.
    Bell TJ; Nagel DJ; Woeller CF; Kottmann RM
    PLoS One; 2022; 17(7):e0271608. PubMed ID: 35901086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.
    Jiang C; Kumar A; Yu Z; Shipman T; Wang Y; McKay RM; Xing C; Le LQ
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37140985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling iPSC-derived human neurofibroma-like tumors in mice uncovers the heterogeneity of Schwann cells within plexiform neurofibromas.
    Mazuelas H; Magallón-Lorenz M; Fernández-Rodríguez J; Uriarte-Arrazola I; Richaud-Patin Y; Terribas E; Villanueva A; Castellanos E; Blanco I; Raya Á; Chojnacki J; Heyn H; Romagosa C; Lázaro C; Gel B; Carrió M; Serra E
    Cell Rep; 2022 Feb; 38(7):110385. PubMed ID: 35172160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target Product Profile for Cutaneous Neurofibromas: Clinical Trials to Prevent, Arrest, or Regress Cutaneous Neurofibromas.
    Ly I; Romo CG; Gottesman S; Kelly KM; Kornacki D; York Z; Lee SY; Rhodes SD; Staedtke V; Steensma MR; Blakeley JO; Wolkenstein P
    J Invest Dermatol; 2023 Aug; 143(8):1388-1396. PubMed ID: 37294242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
    Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.
    Li H; Zhang X; Fishbein L; Kweh F; Campbell-Thompson M; Perrin GQ; Muir D; Wallace M
    Cancer Biol Ther; 2010 Oct; 10(8):758-64. PubMed ID: 20699653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.